Perhaps you have already decided that Volufiline belongs in your next product. You have looked at competing serums, noticed the 3% and 5% labels, and started considering which direction would suit your brand. There is still quite a lot hidden inside that decision, though. A serum intended to sit under morning skincare and makeup has a different brief from one developed for a richer evening routine.
I find the discussion becomes much easier with an actual formula in front of us. We can look at the supporting ingredients, question whether they belong, and decide what we need to learn from the samples. That gives a brand something concrete to work with before committing to a concentration, a bottle or a set of promises for the product page.
Xiran Skincare 3% Volufiline peptide serum and 5% Volufiline serum oil provide two useful references for that discussion. They show how the same lead ingredient can sit within quite different products—and why choosing between them involves more than comparing the numbers on the label.
The first reference is Xiran Skincare 3% Volufiline Spherical Peptide Firming Serum, listed as product XR20260514002P on pages 22 and 26 of our development presentation. Its profile includes a peptide system, HPR, retinyl palmitate, sodium hyaluronate and hydrolyzed sodium hyaluronate alongside Volufiline, and describes a soft, velvety texture. The presentation gives us a formulation concept to examine; it does not establish that this combination outperforms another serum.
For a brand considering a mature-skin product, there is a useful discussion to have here. Is the customer primarily interested in fuller-looking skin, or is she looking for a broader firming serum that also addresses dryness and visible lines? Those ideas can overlap, but the answer changes what deserves the most attention during development.
My preference would be to settle that question before carrying the entire supporting-ingredient combination into a new project. A brand may like the peptide-serum direction while wanting a simpler daily product. Another may be deliberately developing a more involved treatment around visible lines and skin texture. Both could begin with this reference and end up asking for different samples.
The peptide system gives us one possible direction for firmness and smoother-looking skin. The hyaluronate ingredients belong to the hydration side of the formula. Separating those roles helps the brand explain the product without turning every ingredient into another version of the same “plumping” promise. These are formulation intentions to investigate, rather than proof of what the finished serum will achieve.
The retinoids deserve a closer conversation. Their presence in the reference formula does not mean every new version needs them. For a brief centered on visible lines and texture, they may be worth exploring. For a product whose main appeal is daily hydration and comfort, I would ask the team to explain what they contribute before accepting the additional stability, packaging and tolerance considerations. The selected retinoid form and concentration need to be considered with the rest of the formula.
A dry-skin brief could lead us toward a different balance again. Ceramides or other barrier-support ingredients may be relevant, with more attention given to the moisturizing base and how comfortable the sample feels after application. There may be no reason to retain every active from the original reference. The aim is to develop the version that fits this customer, rather than preserve the longest possible ingredient list.
An eye-area product deserves a separate brief, even when the brand wants it to share the facial serum’s ingredient identity. I would want the development discussion to cover how the sample spreads, whether it tends to move toward the eyes, the choice of supporting actives, tolerance and dispensing. A smaller bottle does not resolve those questions.
The intended cosmetic focus might be dryness, fine lines or the appearance of a less cushioned eye contour. That is a different development task from promising to rebuild under-eye fat, and the product’s wording should preserve that distinction.
The percentage question still matters. It simply becomes more useful once the brand understands what is being measured.
Volufiline is a supplied cosmetic raw material with the INCI Hydrogenated Polyisobutene (and) Anemarrhenae Asphodeloides (Root) Extract. A formula described as containing 5% Volufiline is referring to the inclusion level of that commercial raw material, not 5% pure sarsasapogenin. The same distinction applies when discussing the 3% product concept.
When reviewing a manufacturer’s proposal, I would ask for that point to be stated plainly. It helps prevent the brand from comparing unlike numbers or writing packaging copy that implies a different ingredient concentration from the one actually used.
There is also a practical formulation issue. Volufiline is supplied as an oil-like material, so incorporating it is not the same task as adding another water-soluble ingredient to a hydrating serum. Its place in the formula can affect emulsification, clarity, viscosity, distribution and skin feel. Those considerations need to be worked through in the chosen base.
A competitor’s percentage can provide context, but it is a weak development brief on its own. Before requesting a higher number, I would want to know what improvement the brand expects and how that improvement would be assessed. Without those answers, the project risks spending its effort on a label comparison rather than a better-defined product.
The second reference, the 5% Volufiline Serum Oil on page 29 of our presentation, lists cyclopentasiloxane and dimethicone alongside squalane and plant oils, including jojoba and meadowfoam seed oils. This is a different surrounding formula from the peptide serum. The two profiles are not a controlled comparison of 3% versus 5% Volufiline.
With this concept, my attention would move quickly to the sample. The ingredient profile helps us decide what to investigate, but it cannot tell us exactly how much slip, richness or residue the customer will experience. Those details could determine whether the product feels right for the brand.
Consider a serum intended for use before moisturizer, sunscreen and makeup. During sampling, I would review it within that proposed routine as well as on its own, paying attention to spreadability, tackiness and the finish after several minutes. For a richer evening concept, the brand may have different expectations of the after-feel. These are evaluation questions for the proposed product, not results established by the presentation.
This is also where vague feedback can slow the discussion. “Make it more luxurious” leaves the team guessing. A more useful response explains what needs to change: the sample takes too much effort to spread, feels tackier than expected, or leaves more of a film than the intended customer would welcome. Each observation gives the next sample a clearer purpose.
The serum oil may turn out to be the right direction, or sampling may reveal that the brand prefers a lighter emulsion. Either outcome is useful. The point of evaluating a reference is to make that decision before the packaging and marketing have committed the project to something the brand does not actually enjoy using.
Packaging belongs in this conversation because it affects the way the customer handles the formula. A dropper may suit the presentation of a serum oil; an airless pump may fit a treatment-style product. Those are options to evaluate, rather than automatic matches.
The actual sample still needs to work with the proposed pack. Viscosity affects dispensing, some active systems bring light or air protection considerations, and the formula needs compatibility assessment with the container and its components. An attractive bottle is only a candidate until those questions have been addressed.
I would bring the preferred packaging direction into sampling early, while keeping the final choice open. That lets the brand discuss appearance and use together, instead of approving a formula and then discovering that the bottle it wanted is an awkward fit.
Before discussing a performance study, I would ask the brand to write the sentence it hopes to put on the product page. “Helps skin look fuller” asks a different question from a statement about hydration or smoother-looking skin. Getting the proposed wording onto the page makes it easier to discuss what evidence would be relevant.
Those phrases are working claim directions, not benefits already established for a new serum. They still need appropriate support and review for the intended market. I would avoid building the concept around statements such as “grows facial fat” or “replaces dermal filler”; changing the appearance of skin and claiming to create new tissue are very different propositions.
It also helps to separate two testing conversations that are sometimes bundled together. One concerns product quality: whether the formula remains acceptable, whether the preservation strategy is appropriate and whether the packaging works with it. The other concerns performance: what the finished serum can reasonably be said to do.
For quality assessment, the program should reflect the actual formula and pack. Stability work may follow appearance, viscosity, odor and homogeneity under the selected conditions. Packaging compatibility examines the container and formula together, while water-containing products also need an appropriate approach to preservation and microbiological quality. Passing those checks does not, by itself, substantiate a fuller-looking-skin claim.
Performance work should then be selected around the proposed outcome. Standardized photography, structured consumer-perception testing, instrumental measurements or facial imaging may answer different questions. The useful discussion is which method can address the claim—not simply which option produces the largest set of numbers for a brochure.
Our presentation contains a relevant example on page 34: a face-cream testing summary that reports third-party testing involving 33 participants over 28 days. That information concerns the tested cream. It is not evidence of the performance of the peptide serum or serum oil discussed in this article.
For a serum project, I would keep the formula identity and its supporting report together whenever claims are reviewed. Sharing a lead ingredient does not make results interchangeable. This is worth resolving before copywriting begins, when a promising number from one document can easily find its way into a different product’s description.
There is a commercial reason to care about this as well. Evidence from the brand’s own finished formula gives it something specific to explain. Repeating a supplier statistic may introduce the ingredient, but it leaves the customer with unanswered questions about the serum being sold.
An existing formula can be a sensible starting point when it already comes close to the product the brand wants. For a business entering the category, there may be little value in rebuilding a suitable base simply to describe the project as custom-developed.
The private-label route is worth considering when the sample, positioning and available scope of modification fit the brief. The time saving comes from beginning with existing formulation work, allowing more attention to move toward packaging and branding. The trade-off is that the formula may offer less differentiation, so the brand needs to be realistic about what makes its version distinctive.
Before choosing that route, I would confirm what is actually available: the formula version, the changes being proposed and the documentation relevant to the project. A product-development profile gives us a starting point, but it should not be treated as a complete answer to every launch requirement.
Custom development becomes more useful when the changes are central to the product. Perhaps the brand likes the peptide direction but needs a different finish, a particular fragrance approach or a supporting-active combination that fits an established range. Those are specific requirements the team can develop against.
A brief such as, “We want a lightweight Volufiline and peptide serum for women aged 35–55, with a silky finish, minimal fragrance and premium healthy-aging positioning,” gives the discussion a workable starting point. From there, the team can consider the active system, hydration, viscosity, appearance and packaging together. The intended market should be part of the same conversation.
The choice between private label and custom development should follow that brief. If an existing sample already fits closely, extensive changes may add little value. If the differences matter to how the product will be used and understood, they deserve development time. I would make that judgment with the sample and requirements side by side.
A sample approval should make the next stage clearer. It establishes the version the brand intends to take forward, including the agreed texture, appearance and packaging direction. I would want those expectations recorded, rather than left as a general statement that the sample “feels good.”
The remaining work depends on the formula and target market, but the development process described in our materials includes the relevant stability, microbiological and compatibility testing, claims review, pilot production or scale-up, filling, final quality inspection and batch release.
During that handover, the approved sample, written specifications, packaging and supporting documents need to remain connected. If the formula or pack changes, the brand should ask which evaluations need to be revisited. The same applies to marketing: the wording approved for launch should describe the product actually being manufactured and reflect the evidence available for it.
This stage may be less exciting than choosing the lead ingredients, but it is where the brand protects the decisions it has already made. The finished product should still resemble the one it approved—not just in the ingredient story, but in the experience of dispensing and using it.
I would be more confident in a focused serum with a clear place in the customer’s routine than in a complicated formula whose main selling point is a higher percentage. The 3% peptide serum and 5% serum oil are useful precisely because they prompt different questions about the product. Neither reference removes the need to decide what your brand wants to make.
The goal is to create a serum that still makes sense to the customer after the ingredient becomes familiar. At that point, the formula has to offer a reason to keep using it, and the brand needs an honest explanation of what it can deliver.
At Xiran Skincare, we can discuss an existing Volufiline concept or a custom formula around your intended customer, preferred texture and target market. Share those priorities with us so the first development discussion starts with the product you actually want to bring to market.
The standard supplier-recommended inclusion level for Volufiline™ (by Sederma) in cosmetic formulas ranges from 2% to 5%. Rather than simply aiming for the highest percentage, formula performance depends on the overall active system, skin delivery base, and intended use. For instance, a 3% inclusion level paired with a targeted peptide system can deliver exceptional firming results, whereas a 5% level is often utilized in rich serum oils or localized treatment products.
The percentage on a label or formula brief (e.g., 3% or 5%) refers to the commercial raw material blend—which is a solution of Hydrogenated Polyisobutene and Anemarrhenae Asphodeloides Root Extract. It does not mean the product contains 3% or 5% pure Sarsasapogenin (the active phytosterol). Clear formulation briefs should always distinguish between commercial inclusion levels and active constituent concentrations.
Because Volufiline is an oil-soluble ingredient, incorporating it into a purely aqueous base requires effective solubilization or emulsification. It is best formulated within milky emulsions, gel-emulsions, micro-emulsions, or anhydrous serum oils. Attempting to add high levels of Volufiline directly to a thin water base without proper emulsifiers can lead to formula instability, cloudiness, or phase separation.
A: Yes. Volufiline works exceptionally well in multi-pathway formulas:
A: In vitro and clinical evaluation studies conducted on the raw material typically evaluate parameters over 28 to 56 days of consistent, twice-daily application. Visible outcomes—such as smoother skin texture and a more cushioned appearance—depend on finished product formulation, user compliance, and baseline skin condition.
A: Acceptable cosmetic claims focus on the visible appearance of the skin.
